309 related articles for article (PubMed ID: 27009842)
1. Exome and deep sequencing of clinically aggressive neuroblastoma reveal somatic mutations that affect key pathways involved in cancer progression.
Lasorsa VA; Formicola D; Pignataro P; Cimmino F; Calabrese FM; Mora J; Esposito MR; Pantile M; Zanon C; De Mariano M; Longo L; Hogarty MD; de Torres C; Tonini GP; Iolascon A; Capasso M
Oncotarget; 2016 Apr; 7(16):21840-52. PubMed ID: 27009842
[TBL] [Abstract][Full Text] [Related]
2. The genetic landscape of high-risk neuroblastoma.
Pugh TJ; Morozova O; Attiyeh EF; Asgharzadeh S; Wei JS; Auclair D; Carter SL; Cibulskis K; Hanna M; Kiezun A; Kim J; Lawrence MS; Lichenstein L; McKenna A; Pedamallu CS; Ramos AH; Shefler E; Sivachenko A; Sougnez C; Stewart C; Ally A; Birol I; Chiu R; Corbett RD; Hirst M; Jackman SD; Kamoh B; Khodabakshi AH; Krzywinski M; Lo A; Moore RA; Mungall KL; Qian J; Tam A; Thiessen N; Zhao Y; Cole KA; Diamond M; Diskin SJ; Mosse YP; Wood AC; Ji L; Sposto R; Badgett T; London WB; Moyer Y; Gastier-Foster JM; Smith MA; Guidry Auvil JM; Gerhard DS; Hogarty MD; Jones SJ; Lander ES; Gabriel SB; Getz G; Seeger RC; Khan J; Marra MA; Meyerson M; Maris JM
Nat Genet; 2013 Mar; 45(3):279-84. PubMed ID: 23334666
[TBL] [Abstract][Full Text] [Related]
3. Oncogene mutation profiling of pediatric solid tumors reveals significant subsets of embryonal rhabdomyosarcoma and neuroblastoma with mutated genes in growth signaling pathways.
Shukla N; Ameur N; Yilmaz I; Nafa K; Lau CY; Marchetti A; Borsu L; Barr FG; Ladanyi M
Clin Cancer Res; 2012 Feb; 18(3):748-57. PubMed ID: 22142829
[TBL] [Abstract][Full Text] [Related]
4. Somatic mutations in specific and connected subpathways are associated with short neuroblastoma patients' survival and indicate proteins targetable at onset of disease.
Esposito MR; Binatti A; Pantile M; Coppe A; Mazzocco K; Longo L; Capasso M; Lasorsa VA; Luksch R; Bortoluzzi S; Tonini GP
Int J Cancer; 2018 Nov; 143(10):2525-2536. PubMed ID: 29992558
[TBL] [Abstract][Full Text] [Related]
5. Next generation sequencing of microRNAs from isogenic neuroblastoma cell lines isolated before and after treatment.
Roth SA; Knutsen E; Fiskaa T; Utnes P; Bhavsar S; Hald ØH; Løkke C; Mestdagh P; Johansen SD; Flægstad T; Einvik C
Cancer Lett; 2016 Mar; 372(1):128-36. PubMed ID: 26708804
[TBL] [Abstract][Full Text] [Related]
6. Whole-genome sequencing of recurrent neuroblastoma reveals somatic mutations that affect key players in cancer progression and telomere maintenance.
Fransson S; Martinez-Monleon A; Johansson M; Sjöberg RM; Björklund C; Ljungman G; Ek T; Kogner P; Martinsson T
Sci Rep; 2020 Dec; 10(1):22432. PubMed ID: 33384420
[TBL] [Abstract][Full Text] [Related]
7. Deep Sequencing Reveals Occurrence of Subclonal ALK Mutations in Neuroblastoma at Diagnosis.
Bellini A; Bernard V; Leroy Q; Rio Frio T; Pierron G; Combaret V; Lapouble E; Clement N; Rubie H; Thebaud E; Chastagner P; Defachelles AS; Bergeron C; Buchbinder N; Taque S; Auvrignon A; Valteau-Couanet D; Michon J; Janoueix-Lerosey I; Delattre O; Schleiermacher G
Clin Cancer Res; 2015 Nov; 21(21):4913-21. PubMed ID: 26059187
[TBL] [Abstract][Full Text] [Related]
8. Enrichment of Targetable Mutations in the Relapsed Neuroblastoma Genome.
Padovan-Merhar OM; Raman P; Ostrovnaya I; Kalletla K; Rubnitz KR; Sanford EM; Ali SM; Miller VA; Mossé YP; Granger MP; Weiss B; Maris JM; Modak S
PLoS Genet; 2016 Dec; 12(12):e1006501. PubMed ID: 27997549
[TBL] [Abstract][Full Text] [Related]
9. Pan-neuroblastoma analysis reveals age- and signature-associated driver alterations.
Brady SW; Liu Y; Ma X; Gout AM; Hagiwara K; Zhou X; Wang J; Macias M; Chen X; Easton J; Mulder HL; Rusch M; Wang L; Nakitandwe J; Lei S; Davis EM; Naranjo A; Cheng C; Maris JM; Downing JR; Cheung NV; Hogarty MD; Dyer MA; Zhang J
Nat Commun; 2020 Oct; 11(1):5183. PubMed ID: 33056981
[TBL] [Abstract][Full Text] [Related]
10. A comprehensive characterization of rare mitochondrial DNA variants in neuroblastoma.
Calabrese FM; Clima R; Pignataro P; Lasorsa VA; Hogarty MD; Castellano A; Conte M; Tonini GP; Iolascon A; Gasparre G; Capasso M
Oncotarget; 2016 Aug; 7(31):49246-49258. PubMed ID: 27351283
[TBL] [Abstract][Full Text] [Related]
11. Genetic Alterations Detected by Targeted Next-generation Sequencing and Their Clinical Implications in Neuroblastoma.
Koh KN; Lee JY; Lim J; Shin J; Kang SH; Suh JK; Kim H; Im HJ; Namgoong JM; Kim DY; Jang SJ; Chun SM
Anticancer Res; 2020 Dec; 40(12):7057-7065. PubMed ID: 33288603
[TBL] [Abstract][Full Text] [Related]
12. Whole-exome sequencing reveals recurrent somatic mutation networks in cancer.
Liu X; Wang J; Chen L
Cancer Lett; 2013 Nov; 340(2):270-6. PubMed ID: 23153794
[TBL] [Abstract][Full Text] [Related]
13. BLM germline and somatic PKMYT1 and AHCY mutations: Genetic variations beyond MYCN and prognosis in neuroblastoma.
Novak EM; Halley NS; Gimenez TM; Rangel-Santos A; Azambuja AM; Brumatti M; Pereira PL; Vince CS; Giorgi RR; Bendit I; Cristofani LM; Odone-Filho V
Med Hypotheses; 2016 Dec; 97():22-25. PubMed ID: 27876123
[TBL] [Abstract][Full Text] [Related]
14. Appearance of the novel activating F1174S ALK mutation in neuroblastoma correlates with aggressive tumor progression and unresponsiveness to therapy.
Martinsson T; Eriksson T; Abrahamsson J; Caren H; Hansson M; Kogner P; Kamaraj S; Schönherr C; Weinmar J; Ruuth K; Palmer RH; Hallberg B
Cancer Res; 2011 Jan; 71(1):98-105. PubMed ID: 21059859
[TBL] [Abstract][Full Text] [Related]
15. Research progress of neuroblastoma related gene variations.
Cao Y; Jin Y; Yu J; Wang J; Yan J; Zhao Q
Oncotarget; 2017 Mar; 8(11):18444-18455. PubMed ID: 28055978
[TBL] [Abstract][Full Text] [Related]
16. Mutational dynamics between primary and relapse neuroblastomas.
Schramm A; Köster J; Assenov Y; Althoff K; Peifer M; Mahlow E; Odersky A; Beisser D; Ernst C; Henssen AG; Stephan H; Schröder C; Heukamp L; Engesser A; Kahlert Y; Theissen J; Hero B; Roels F; Altmüller J; Nürnberg P; Astrahantseff K; Gloeckner C; De Preter K; Plass C; Lee S; Lode HN; Henrich KO; Gartlgruber M; Speleman F; Schmezer P; Westermann F; Rahmann S; Fischer M; Eggert A; Schulte JH
Nat Genet; 2015 Aug; 47(8):872-7. PubMed ID: 26121086
[TBL] [Abstract][Full Text] [Related]
17. Study of chromatin remodeling genes implicates SMARCA4 as a putative player in oncogenesis in neuroblastoma.
Bellini A; Bessoltane-Bentahar N; Bhalshankar J; Clement N; Raynal V; Baulande S; Bernard V; Danzon A; Chicard M; Colmet-Daage L; Pierron G; Le Roux L; Planchon JM; Combaret V; Lapouble E; Corradini N; Thebaud E; Gambart M; Valteau-Couanet D; Michon J; Louis-Brennetot C; Janoueix-Lerosey I; Defachelles AS; Bourdeaut F; Delattre O; Schleiermacher G
Int J Cancer; 2019 Nov; 145(10):2781-2791. PubMed ID: 31018240
[TBL] [Abstract][Full Text] [Related]
18. Whole exome sequencing of rare aggressive breast cancer histologies.
Dieci MV; Smutná V; Scott V; Yin G; Xu R; Vielh P; Mathieu MC; Vicier C; Laporte M; Drusch F; Guarneri V; Conte P; Delaloge S; Lacroix L; Fromigué O; André F; Lefebvre C
Breast Cancer Res Treat; 2016 Feb; 156(1):21-32. PubMed ID: 26907767
[TBL] [Abstract][Full Text] [Related]
19. [Lung cancer molecular testing, what role for Next Generation Sequencing and circulating tumor DNA].
Pécuchet N; Legras A; Laurent-Puig P; Blons H
Ann Pathol; 2016 Jan; 36(1):80-93. PubMed ID: 26803564
[TBL] [Abstract][Full Text] [Related]
20. Deep Sequencing in Conjunction with Expression and Functional Analyses Reveals Activation of FGFR1 in Ewing Sarcoma.
Agelopoulos K; Richter GH; Schmidt E; Dirksen U; von Heyking K; Moser B; Klein HU; Kontny U; Dugas M; Poos K; Korsching E; Buch T; Weckesser M; Schulze I; Besoke R; Witten A; Stoll M; Köhler G; Hartmann W; Wardelmann E; Rossig C; Baumhoer D; Jürgens H; Burdach S; Berdel WE; Müller-Tidow C
Clin Cancer Res; 2015 Nov; 21(21):4935-46. PubMed ID: 26179511
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
